S05216 Summary:
BILL NO | S05216A |
  | |
SAME AS | SAME AS A03072-A |
  | |
SPONSOR | SAVINO |
  | |
COSPNSR | ADDABBO, AVELLA, COMRIE, CROCI, GALLIVAN, GOLDEN, GRIFFO, HANNON, KENNEDY, KLEIN, LATIMER, PANEPINTO, PARKER, PERALTA, PERKINS, PERSAUD, RANZENHOFER, RITCHIE, SANDERS, STAVISKY, VALESKY, VENDITTO |
  | |
MLTSPNSR | |
  | |
Amd §207, Pub Health L | |
  | |
Creates an education and outreach program for the autoimmune disease known as lupus; provides for an advisory council consisting of representatives of people with lupus and their families and health care providers who specialize in treating lupus. |
S05216 Actions:
BILL NO | S05216A | |||||||||||||||||||||||||||||||||||||||||||||||||
  | ||||||||||||||||||||||||||||||||||||||||||||||||||
05/07/2015 | REFERRED TO HEALTH | |||||||||||||||||||||||||||||||||||||||||||||||||
05/28/2015 | REPORTED AND COMMITTED TO FINANCE | |||||||||||||||||||||||||||||||||||||||||||||||||
01/06/2016 | REFERRED TO HEALTH | |||||||||||||||||||||||||||||||||||||||||||||||||
05/04/2016 | REPORTED AND COMMITTED TO FINANCE | |||||||||||||||||||||||||||||||||||||||||||||||||
05/16/2016 | AMEND AND RECOMMIT TO FINANCE | |||||||||||||||||||||||||||||||||||||||||||||||||
05/16/2016 | PRINT NUMBER 5216A | |||||||||||||||||||||||||||||||||||||||||||||||||
06/07/2016 | COMMITTEE DISCHARGED AND COMMITTED TO RULES | |||||||||||||||||||||||||||||||||||||||||||||||||
06/07/2016 | ORDERED TO THIRD READING CAL.1490 | |||||||||||||||||||||||||||||||||||||||||||||||||
06/08/2016 | PASSED SENATE | |||||||||||||||||||||||||||||||||||||||||||||||||
06/08/2016 | DELIVERED TO ASSEMBLY | |||||||||||||||||||||||||||||||||||||||||||||||||
06/08/2016 | referred to ways and means | |||||||||||||||||||||||||||||||||||||||||||||||||
06/15/2016 | substituted for a3072a | |||||||||||||||||||||||||||||||||||||||||||||||||
06/15/2016 | ordered to third reading rules cal.330 | |||||||||||||||||||||||||||||||||||||||||||||||||
06/15/2016 | passed assembly | |||||||||||||||||||||||||||||||||||||||||||||||||
06/15/2016 | returned to senate | |||||||||||||||||||||||||||||||||||||||||||||||||
11/16/2016 | DELIVERED TO GOVERNOR | |||||||||||||||||||||||||||||||||||||||||||||||||
11/28/2016 | SIGNED CHAP.479 |
S05216 Committee Votes:
Go to topS05216 Floor Votes:
Yes
Abbate
Yes
Crespo
Yes
Gottfried
Yes
Lopez
Yes
Palumbo
Yes
Simon
Yes
Abinanti
Yes
Crouch
Yes
Graf
Yes
Lupardo
Yes
Paulin
Yes
Simotas
Yes
Arroyo
Yes
Curran
Yes
Gunther
Yes
Lupinacci
Yes
Peoples-Stokes
Yes
Skartados
Yes
Aubry
Yes
Cusick
Yes
Harris
Yes
Magee
Yes
Perry
Yes
Skoufis
Yes
Barclay
Yes
Cymbrowitz
Yes
Hawley
Yes
Magnarelli
Yes
Pichardo
Yes
Solages
Yes
Barrett
Yes
Davila
Yes
Hevesi
Yes
Malliotakis
Yes
Pretlow
Yes
Stec
Yes
Barron
Yes
DenDekker
Yes
Hikind
Yes
Markey
Yes
Quart
Yes
Steck
Yes
Benedetto
Yes
Dilan
Yes
Hooper
Yes
Mayer
Yes
Ra
Yes
Stirpe
Yes
Bichotte
Yes
Dinowitz
Yes
Hunter
Yes
McDonald
Yes
Raia
Yes
Tedisco
Yes
Blake
ER
DiPietro
Yes
Hyndman
Yes
McDonough
Yes
Ramos
Yes
Tenney
Yes
Blankenbush
Yes
Duprey
Yes
Jaffee
Yes
McKevitt
Yes
Richardson
Yes
Thiele
Yes
Brabenec
Yes
Englebright
Yes
Jean-Pierre
Yes
McLaughlin
Yes
Rivera
Yes
Titone
Yes
Braunstein
Yes
Fahy
Yes
Johns
Yes
Miller
Yes
Robinson
Yes
Titus
ER
Brennan
Yes
Farrell
Yes
Joyner
Yes
Montesano
Yes
Rodriguez
Yes
Walker
Yes
Brindisi
ER
Finch
Yes
Katz
Yes
Morelle
Yes
Rosenthal
Yes
Walter
Yes
Bronson
Yes
Fitzpatrick
Yes
Kavanagh
Yes
Mosley
Yes
Rozic
Yes
Weinstein
Yes
Buchwald
Yes
Friend
Yes
Kearns
Yes
Moya
Yes
Russell
Yes
Weprin
Yes
Butler
Yes
Galef
ER
Kim
Yes
Murray
Yes
Ryan
Yes
Williams
Yes
Cahill
Yes
Gantt
Yes
Kolb
Yes
Nojay
Yes
Saladino
Yes
Woerner
Yes
Cancel
Yes
Garbarino
Yes
Lalor
Yes
Nolan
Yes
Santabarbara
Yes
Wozniak
Yes
Castorina
Yes
Giglio
Yes
Lavine
Yes
Oaks
Yes
Schimel
Yes
Wright
Yes
Ceretto
Yes
Gjonaj
Yes
Lawrence
Yes
O'Donnell
Yes
Schimminger
Yes
Zebrowski
Yes
Colton
Yes
Glick
Yes
Lentol
Yes
Ortiz
Yes
Seawright
Yes
Mr. Speaker
Yes
Cook
Yes
Goldfeder
Yes
Lifton
Yes
Otis
ER
Sepulveda
Yes
Corwin
Yes
Goodell
Yes
Linares
Yes
Palmesano
Yes
Simanowitz
‡ Indicates voting via videoconference
S05216 Text:
Go to top STATE OF NEW YORK ________________________________________________________________________ 5216--A 2015-2016 Regular Sessions IN SENATE May 7, 2015 ___________ Introduced by Sens. SAVINO, ADDABBO, AVELLA, COMRIE, CROCI, GALLIVAN, GOLDEN, GRIFFO, HANNON, KENNEDY, KLEIN, LATIMER, PANEPINTO, PARKER, PERALTA, PERKINS, RANZENHOFER, RITCHIE, STAVISKY, VALESKY, VENDITTO -- read twice and ordered printed, and when printed to be committed to the Committee on Health -- recommitted to the Committee on Health in accordance with Senate Rule 6, sec. 8 -- reported favorably from said committee and committed to the Committee on Finance -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee AN ACT to amend the public health law, in relation to the lupus educa- tion and outreach program The People of the State of New York, represented in Senate and Assem- bly, do enact as follows: 1 Section 1. Legislative intent. The legislature hereby finds the 2 following: 3 (a) Lupus is a serious, complex, debilitating autoimmune disease that 4 can cause inflammation and tissue damage to virtually any organ system 5 in the body, including the skin, joints, other connective tissue, blood 6 and blood vessels, heart, lungs, kidney, and brain. 7 (b) Lupus research estimates that approximately one and a half to two 8 million Americans live with some form of lupus; lupus affects women nine 9 times more often than men and eighty percent of newly diagnosed cases of 10 lupus develop among women of childbearing age. 11 (c) Lupus disproportionately affects women of color -- it is two to 12 three times more common among African-Americans, Hispanics, Asians and 13 Native Americans and is generally more prevalent in minority populations 14 -- a health disparity that remains unexplained. According to the Centers 15 for Disease Control and Prevention the rate of lupus mortality has 16 increased since the late 1970s and is higher among older African-Ameri- 17 can women. EXPLANATION--Matter in italics (underscored) is new; matter in brackets [] is old law to be omitted. LBD01779-02-6S. 5216--A 2 1 (d) No new drugs have been approved by the U.S. Food and Drug Adminis- 2 tration specifically for lupus in nearly forty years and while current 3 treatments for the disease can be effective, they can lead to damaging 4 side effects. 5 (e) The pain and fatigue associated with lupus can threaten people's 6 ability to live independently, make it difficult to maintain employment 7 and lead normal lives, and one in five people with lupus is disabled by 8 the disease, and consequently receives support from government programs, 9 including Medicare, Medicaid, social security disability, and social 10 security supplemental income. 11 (f) The estimated average annual cost of medical treatment for an 12 individual with lupus can range between ten thousand dollars and thirty 13 thousand dollars; for people who have the most serious form of lupus, 14 medical costs can greatly exceed this amount, causing a significant 15 economic, emotional and social burden to the entire family and society. 16 (g) More than half of the people with lupus suffer four or more years 17 and visit three or more physicians before obtaining a diagnosis of 18 lupus; early diagnosis of and commencement of treatment for lupus can 19 prevent or reduce serious organ damage, disability, and death. 20 (h) Despite the magnitude of lupus and its impact on individuals and 21 families, health professional and public understanding of lupus remains 22 low; only one of five Americans can provide even basic information about 23 lupus, and awareness of lupus is lowest among adults ages eighteen to 24 thirty-four -- the age group most likely to develop symptoms of lupus. 25 (i) Lupus is a significant national health issue that deserves a 26 comprehensive and coordinated response by state and federal governments 27 with involvement of the health care provider, patient, and public health 28 communities. 29 § 2. Subdivision 1 of section 207 of the public health law is amended 30 by adding a new paragraph (m) to read as follows: 31 (m) Lupus, a debilitating autoimmune disease that can cause inflamma- 32 tion and tissue damage to virtually any organ system in the body, 33 including the skin, joints, other connective tissue, blood and blood 34 vessels, heart, lung, kidney and brain, and which affects women, partic- 35 ularly women of color, in a disproportionate manner; provided that the 36 program shall include an advisory council under this section that shall 37 include representatives of people with lupus and their families and 38 health care providers who specialize in treating lupus, among others. 39 § 3. Subdivision 7 of section 207 of the public health law, as amended 40 by section 16 of part A of chapter 109 of the laws of 2010, is amended 41 to read as follows: 42 7. In addition to state funds appropriated for programs under this 43 section, the commissioner may accept grants from public or private 44 sources for these programs. The commissioner, in administering this 45 section, shall seek to coordinate the department's programs with other 46 public and private programs, and may undertake joint or cooperative 47 programs with other public or private entities, including making grants 48 (within amounts appropriated therefor and consistent with applicable 49 law) to public or not-for-profit entities. 50 § 4. This act shall take effect immediately.